Vascular Gene Therapy Unit, School of Biomedicine, Manchester Academic Health Science Centre, Room 3.26, Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT, UK.
Viruses. 2010 Feb;2(2):334-371. doi: 10.3390/v2020334. Epub 2010 Jan 27.
Cardiovascular disease represents the most common cause of mortality in the developed world but, despite two decades of promising pre-clinical research and numerous clinical trials, cardiovascular gene transfer has so far failed to demonstrate convincing benefits in the clinical setting. In this review we discuss the various targets which may be suitable for cardiovascular gene therapy and the viral vectors which have to date shown the most potential for clinical use. We conclude with a summary of the current state of clinical cardiovascular gene therapy and the key trials which are ongoing.
心血管疾病是发达国家最常见的死亡原因，但尽管在过去二十年中有大量有前景的临床前研究和临床试验，心血管基因转移迄今为止未能在临床环境中证明令人信服的益处。在这篇综述中，我们讨论了可能适合心血管基因治疗的各种靶标以及迄今为止显示出最有临床应用潜力的病毒载体。最后，我们总结了当前心血管基因治疗的临床状态和正在进行的关键试验。
